Overview

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in South Africa, Europe and North America. The aim of this trial is to compare efficacy and safety of NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar), as add-on to subject's ongoing treatment with metformin and/or dipeptyl peptidase 4 (DPP-4) inhibitors, in patients with type 2 diabetes being treated with oral anti-diabetic drugs (OADs) qualifying for intensified treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc